Abstract:Introduction Obesity is a major risk factor for heart failure (HF); each one unit increase in BMI potentiates HF risk by 5% and 7% in men and women, respectively. In 2022, at Franciscan Health, Indianapolis, an Obesity Task Force was commissioned to tackle obesity by surveying existing local resources, develop clinical pathways, and institute a cardiology-driven obesity clinic for our outpatient HF patients. Hypothesis The cardiology-driven obesity clinic would lead to improved weight loss and subsequent improvement in the burden of HF symptoms, improved functional status, and reduction in HF hospitalizations. Methods Our multidisciplinary obesity task force including cardiology, endocrinology, bariatrics, primary care, nurses, health coaches and lifestyle program administrators developed an obesity HF algorithm. HF patients were identified in both the inpatient and outpatient setting and referred to a designated HF advanced practice provider as an outpatient. Requirements for referral included diagnosis of HF, BMI ≥30 and motivation to participate in lifestyle modifications. Lifestyle modifications included calorie/macronutrient tracking, appropriate exercise goals, educational materials on the DASH diet as well as videos on approaches to making dietary changes. Utilizing a shared decision-making process, patients were screened for candidacy of glucagon-like-peptide-1 (GLP-1) agonist. Each patient was also offered opportunity for referral to lifestyle programs that included health coaches. Patients started on the GLP-1 were seen every 4-6 weeks for dose titration and follow-up. Results Over a six-month time frame, 30 patients were seen in the obesity clinic (28 HFpEF, 2 HFrEF, 11 men, 19 women, mean age 58 yo, mean BMI 45 kg/m2, 8 with type II diabetes). Of the 30 patients, 12 initiated a GLP-1 agonist with another 10 attempted but declined by insurance. Two out of 12 achieved maximum GLP-1 dose. On average, patients have lost 10% of their starting weight with a range of 5-22%. All 30 patients were offered referral to lifestyle programs. Three patients started and stopped attending (none of them are currently on GLP-1), 8 are actively participating (5 are on GLP-1, 3 are lifestyle alone), and 19 declined referral. Of the patients who chose lifestyle alone, two have lost an average 4.4% starting body weight and one has gained weight. No patients have been admitted for HF exacerbation since being evaluated in the Obesity Clinic. Conclusions Treatment of obesity in the HF population represents a significant unmet medical need. Here we describe our approach to tacking this important risk factor by instituting a cardiology-driven obesity clinic for our outpatient HF patients. In the short time since implementation, we have seen meaningful reductions in weight in the majority of patients by combining a GLP-1 agent and lifestyle modifications. Unfortunately, GLP-1 insurance coverage remains a significant barrier, particularly for non-diabetic patients. Further follow-up will be critical to evaluate the impact our obesity clinic on sustainability of weight loss, impacts on functional status, as well as relevant HF metrics.

How Would You Manage This Patient With Obesity? Grand Rounds Discussion From Beth Israel Deaconess Medical Center

Management of Obesity: Office-Based Strategies

Therapeutic advances in obesity management: an overview of the therapeutic interventions

Role of Glucagon‐Like Peptide‐1 Receptor Agonists in Achieving Weight Loss and Improving Cardiovascular Outcomes in People With Overweight and Obesity

Healthcare professionals' perceptions and management of obesity & knowledge of glucagon, GLP-1, GIP receptor agonists, and dual agonists

Approach to Obesity Treatment in Primary Care

Pharmacotherapy of Weight‐loss and Obesity with a Focus on GLP 1‐Receptor Agonists

Obesity Medicine Intervention at an Academic Medical Center in a Resource-Limited Population Shows Promise

Obesity management in the pediatric patient

Attitudes, Perceptions, and Practices Among Endocrinologists Managing Obesity

Weight Loss and Maintenance Related to the Mechanism of Action of Glucagon-Like Peptide 1 Receptor Agonists

Obesity management for the treatment of type 2 diabetes: emerging evidence and therapeutic approaches

Lifestyle modification approaches for the treatment of obesity in adults.

Effectiveness of pharmacological interventions for managing obesity in children and adolescents: A systematic review and meta-analysis framed using minimal important difference estimates based on GRADE guidance to inform a clinical practice guideline

Current and future state of pharmacological management of pediatric obesity

Impact Of An Embedded Obesity Clinic Within A Community Hospital Heart Failure Program

Effectiveness and safety of drugs for obesity

Pharmacologic management of obesity: Updates on approved medications, indications and risks

Physician Involvement in the Management of Obesity as a Primary Medical Condition

GLP-1 Agonists for Weight Loss: Pharmacology and Clinical Implications

Clinical Considerations Regarding the Use of Obesity Pharmacotherapy in Adolescents with Obesity